Dear Dr. Fisher:

Please refer to your supplemental new drug applications dated December 20, 2005, received December 21, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Serevent Diskus (salmeterol xinafoate inhalation powder), and Advair Diskus (fluticasone propionate and salmeterol inhalation powder).

We acknowledge receipt of your submissions dated January 5, March 31, May 22, and June 26, 2006. These supplemental new drug applications provide for changes to the CLINICAL PHARMAOCLOGY section of the Package Insert including the results of a drug interaction study.

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert) and submitted labeling (package insert submitted May 22, 2006, for NDA 20-692, and package insert submitted June 26, 2006, for NDA 21-077).

Please submit an electronic version or 20 paper copies of the FPL as soon as it is available (no more than 30 days after it is printed). If paper copies are submitted, individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate these submissions "FPL for approved supplement NDA 20-692/S-028, and NDA 21-077/S-027." Approval of these submissions by FDA is not required before the labeling is used.
In addition, submit three copies of the introductory promotional materials that you propose to use for these products. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this Division and two copies of both the promotional materials and the package inserts directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
Food and Drug Administration
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Ms. Akilah Green, Senior Regulatory Management Officer, at (301) 796-1219.

Sincerely,

Badrul A. Chowdhury, M.D., Ph.D.
Director
Division of Pulmonary Allergy Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Badrul Chowdhury